Chemotherapy has helped make the most common childhood cancer one of the most curable, but researchers have evidence that the treatment may also prime some patients for relapse. Results published in the journal Blood reported that treatment-induced mutations cause drug resistance in some patients whose acute lymphoblastic leukemia (ALL) returns.
“Our study reveals the evolution dynamics of pediatric ALL, which suggest for the first time that chemotherapy treatment, particularly thiopurines, can cause mutations that lead to drug resistance in patients,” said study co-corresponding author Jinghui Zhang, Ph.D., chair of the St. Jude Children’s Research Hospital Department of Computational Biology. Thiopurines are a class of drugs used in most phases of ALL treatment.
The study involved 103 young ALL patients who relapsed. Most relapsed nine or more months after diagnosis. The analysis revealed that about 20% of these patients had treatment-related mutations at relapse, some associated with drug resistance. “The mutational signatures are specific and therapy-related, as they are only present in the genomes of relapsed ALL patients but not in other pediatric or adult cancer genomes,” Zhang said.
The findings underscore the need for less toxic therapies and precision-medicine approaches, said co-corresponding author Ching-Hon Pui, M.D., chair of the St. Jude Department of Oncology. Candidates in development include immunotherapies such as CAR-T cells and bispecific antibodies.
“This study points to the potential need to individualize therapy when drug resistant mutations emerge in ALL”, said co-corresponding author Jun J. Yang, Ph.D., of the St. Jude Departments of Oncology and Pharmaceutical Sciences. The other co-corresponding author is Bin-Bing Zhou, Ph.D., of Shanghai Children’s Medical Center and National Children’s Medical Center and the Shanghai Jiao Tong University School of Medicine.
Relapse remains leading cause of death
ALL is the most common childhood cancer. With current treatment, more than 90% of pediatric patients become long-term survivors. The prognosis is dismal for patients whose leukemia returns. Relapse accounts for 70 to 80% of ALL patient deaths.
While previous studies had identified relapse-specific drug resistance mutations, the origin of those mutations was unclear. Some researchers proposed that ALL relapse was driven by drug-resistant leukemic cells present at diagnosis.
Whole genome sequencing analysis
The children in this study were treated in China. They underwent whole genome sequencing of leukemic cells collected at the diagnosis and relapse as well as normal DNA. The analysis also included targeted deep sequencing of leukemic cells collected regularly during treatment of 16 patients.
Researchers identified relapse-specific acquired mutations in 12 genes involved in drug response, including FPGS, a novel, relapse-related gene. The analysis also revealed two novel mutational patterns or signatures. Researchers showed thiopurines caused one of the new mutational signatures. Additional research showed the mutations lead to multi-drug resistance.
Drug resistance and relapse timeline
The timeline of relapse of patients in this study and the presence of relapse-specific mutations in the 12 genes involved in drug response provided insight into the cause.
Most patients, 55%, relapsed nine to 36 months after diagnosis but before treatment ended. This group had the most relapse-specific mutations in the 12 drug-resistance genes, particularly compared to patients who relapsed earlier. Mathematical modeling, mutational analysis and other evidence indicated that earlier relapse was likely caused by drug-resistant tumor cells present at diagnosis.
Investigators proposed a two-step process to explain later relapse. The model suggested that relapse occurred when partially drug-resistant tumor cells that were present at diagnosis acquired treatment-related mutations. The now drug-resistant cells divide and eventually cause relapse.
“This suggests drug resistance is not a foregone conclusion,” Yang said. “It may be preventable through changes in the dosage or timing of treatment.” Based on the findings, Pui said screening relapsed patients for drug-resistance mutations may be indicated.
The first authors are Samuel Brady, Ph.D., and Xiaotu Ma, Ph.D., of St. Jude; Benshang Li and Shuhong Zhang, of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine; Yingchi Zhang, of the Chinese Academy of Medical Sciences and Peking Union Medical College; and Yongjin Li, of the Anhui Medical University, China. The other authors were Karol Szlachta, Li Dong, Yu Liu, Diane Flasch, Heather Mulder, Yanling Liu, Liqing Tian, Kohei Hagiwara, Ke Xu, Xin Zhou, Edgar Sioson, Ying Shao, Ting-Nien Lin, Michael Rusch, Michael Edmonson, John Easton, Cheng Cheng and James R. Downing, of St. Jude; and researchers from other medical centers, universities and institutions in the U.S. and China.
In the U.S., the research was funded in part by the National Cancer Institute, part of the National Institutes of Health; and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.